Drug intelligence / Profile preview

nogitecan

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous

Overview

Nogitecan is a **camptothecin-derived topoisomerase I inhibitor**, structurally and mechanistically related to topotecan and irinotecan. Nogitecan inhibits the enzyme **topoisomerase I**, which is essential for DNA replication. By stabilizing the DNA-topoisomerase I complex and preventing the religation of single-strand DNA breaks, nogitecan induces DNA damage, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing cancer cells. Nogitecan has been investigated primarily as an **antineoplastic agent** for various solid tumors in early-phase clinical studies.

Other names: nogitecan

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on nogitecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nogitecan.

Explore the full profile